Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STS | P08842 | 2/20 | 0.57 |
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.55 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.53 |
| ▸ | KDM1A | O60341 | 1/20 | 0.52 |
| ▸ | CACNB4 | O00305 | 2/20 | 0.50 |
| ▸ | CACNA1A | O00555 | 2/20 | 0.50 |
| ▸ | CACNA1G | O43497 | 2/20 | 0.50 |
| ▸ | CACNG3 | O60359 | 2/20 | 0.50 |
| ▸ | CACNA1F | O60840 | 2/20 | 0.50 |
| ▸ | CACNA1H | O95180 | 2/20 | 0.50 |
| ▸ | CACNB3 | P54284 | 2/20 | 0.50 |
| ▸ | CACNA2D1 | P54289 | 2/20 | 0.50 |
| ▸ | CACNG7 | P62955 | 2/20 | 0.50 |
| ▸ | CACNA1B | Q00975 | 2/20 | 0.50 |
| ▸ | CACNA1D | Q01668 | 2/20 | 0.50 |
| ▸ | CACNB1 | Q02641 | 2/20 | 0.50 |
| ▸ | CACNG1 | Q06432 | 2/20 | 0.50 |
| ▸ | CACNB2 | Q08289 | 2/20 | 0.50 |
| ▸ | CACNA1S | Q13698 | 2/20 | 0.50 |
| ▸ | CACNA1C | Q13936 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29731062 | 1.00 | STS (0.57) | STSGPR119EPHX2KDM1ACACNB4 | |
| SCHEMBL30876497 | 0.88 | GPR119 (0.57) | GPR119KDM1AHRH3USP30 | |
| SCHEMBL1809399 | 0.88 | GPR119 (0.57) | GPR119KDM1AHRH3USP30 | |
| SCHEMBL29120051 | 0.88 | USP30 (0.51) | STSGPR119EPHX2CACNB4CACNA1A | |
| SCHEMBL7722029 | 0.87 | STS (0.57) | STSGPR119CACNB4CACNA1ACACNA1G | |
| SCHEMBL6481542 | 0.86 | GPR119 (0.62) | GPR119EPHX2KDM1AHRH3USP30 | |
| SCHEMBL520668 | 0.86 | KDM1A (0.58) | GPR119KDM1AHRH3USP30 | |
| SCHEMBL29796027 | 0.86 | KDM1A (0.58) | GPR119KDM1AHRH3USP30 | |
| SCHEMBL13242428 | 0.86 | USP30 (0.51) | STSGPR119HRH3USP30TP53 | |
| SCHEMBL15994319 | 0.86 | GPR119 (0.55) | GPR119KDM1AHRH3USP30 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114555573-A | Prostaglandin E2(PGE2)EP4Receptor antagonists | 多曼治疗学公司 | 2022-05-27 | — | — | CN | disclosed |
| US-11186564-B2 | Dual NAV1.2/5HT2a inhibitors for treating CNS disorders | SUNOVION PHARMACEUTICALS INC. (US) | 2021-11-30 | — | — | US | disclosed |
| US-20190194163-A1 | DUAL NAV1.2/5HT2a INHIBITORS FOR TREATING CNS DISORDERS | SUNOVION PHARMACEUTICALS INC. (US) | 2019-06-27 | — | — | US | disclosed |
| WO-2018026371-A1 | DUAL NAV1.2/5HT2A INHIBITORS FOR TREATING CNS DISORDERS | SUNOVION PHARMACEUTICALS INC. (US) | 2018-02-08 | — | — | WO | disclosed |
| EP-1465631-B1 | PYRIMIDINE A2B SELECTIVE ANTAGONIST COMPOUNDS, THEIR SYNTHESIS AND USE | OSI PHARM INC (US) | 2010-02-24 | — | — | EP | disclosed |
| US-7501407-B2 | Pyrimidine A2B selective antagonist compounds, their synthesis and use | OSI PHARMACEUTICALS, INC. (US) | 2009-03-10 | — | — | US | disclosed |
| US-6916804-B2 | Pyrimidine A2b selective antagonist compounds, their synthesis and use | OSI PHARMACEUTICALS, INC. (US) | 2005-07-12 | — | — | US | disclosed |
| US-20050119271-A1 | Pyrimidine A2B selective antagonist compounds, their synthesis and use | OSI PHARMACEUTICALS, INC. | 2005-06-02 | — | — | US | disclosed |
| EP-1465631-A4 | PYRIMIDINE A2B SELECTIVE ANTAGONIST COMPOUNDS, THEIR SYNTHESIS AND USE | OSI PHARM INC (US) | 2005-03-30 | — | — | EP | disclosed |
| EP-1465631-A2 | PYRIMIDINE A2B SELECTIVE ANTAGONIST COMPOUNDS, THEIR SYNTHESIS AND USE | OSI Pharmaceuticals, Inc. (US) | 2004-10-13 | — | — | EP | disclosed |
| US-20030162764-A1 | Pyrimidine A2b selective antagonist compounds, their synthesis and use | OSI PHARMACEUTICALS, INC. | 2003-08-28 | — | — | US | disclosed |
| WO-2003053366-A2 | PYRIMIDINE A2B SELECTIVE ANTAGONIST COMPOUNDS, THEIR SYNTHESIS AND USE | OSI PHARMACEUTICALS, INC. (US) | 2003-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190194163-A1 | DUAL NAV1.2/5HT2a INHIBITORS FOR TREATING CNS DISORDERS | SCN2A, HTR2A, HTR2C | STS 3307/4885GPR119 1545/4885EPHX2 2521/4885 |
| US-20050119271-A1 | Pyrimidine A2B selective antagonist compounds, their synthesis and use | ADORA2B, ADORA2A, ADORA3 | STS 2383/4885GPR119 263/4885EPHX2 604/4885 |
| US-11186564-B2 | Dual NAV1.2/5HT2a inhibitors for treating CNS disorders | SCN2A, HTR2A, HTR2C | STS 3307/4885GPR119 1545/4885EPHX2 2521/4885 |
| US-20030162764-A1 | Pyrimidine A2b selective antagonist compounds, their synthesis and use | ADORA2B, ADORA2A, ADORA3 | STS 1622/4885GPR119 206/4885EPHX2 533/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.